Tucatinib and capecitabine plus spinal trastuzumab for HER2+ cancer
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 2 trial tests a combination of tucatinib and capecitabine (taken by mouth) plus trastuzumab delivered into the spinal fluid, to treat breast cancer that has spread to the leptomeninges (lining around the brain/spinal cord). It may help reduce cancer activity in the spinal fluid and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can give informed consent (or a trusted person can confirm consent if you can’t sign).
- Your breast cancer is metastatic and HER2-positive, confirmed by HER2 testing (IHC, FISH, or ISH).
- Your cancer has confirmed leptomeningeal spread, either on MRI or by finding cancer cells in spinal fluid (CSF) within 28 days.
- Your general strength is good enough (ECOG 0–2), and you’re expected to live at least 2 months.
- You have blood, liver, kidney, and heart test results that meet trial thresholds (including specific ECG and heart pumping measures).
- You are not taking certain medicines that conflict with the study drugs, and you have not used tucatinib or capecitabine before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (tucatinib and trastuzumab) for people with a specific gene change (HER3 mutation) in advanced breast cancer that has spread or cannot be removed by surgery. It may be an option if you have already had at least two previous treatments.
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
This trial tests a combination of three targeted drugs (tucatinib, trastuzumab, and capecitabine) along with radiation to the brain or spine for people whose HER2-positive breast cancer has spread to the lining of the brain or spinal cord. The goal is to see if this treatment is safe and effective.
This study watches how well a three-drug combination (tucatinib, capecitabine, and trastuzumab) works for women with breast cancer that has spread to other parts of the body and has a protein called HER2. You'll be treated as you normally would be in a clinic, and researchers will track how you respond.
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
This Phase 2 study tests tucatinib plus T-DM1 (ado-trastuzumab emtansine) in people with HER2-positive metastatic solid tumors that have spread to the brain. It aims to shrink brain and body tumors and help control cancer that is progressing in the brain.
Hear when a new Leptomeningeal Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.